Lin Jonathan K, Liang Jonathan
Otolaryngologist in the Department of Head and Neck Surgery at the Oakland Medical Center in CA.
Perm J. 2018;22:17-086. doi: 10.7812/TPP/17-086.
Ewing sarcoma (ES) of the sinonasal tract and associated primitive neuroectodermal tumors are rare. To our knowledge, only 10 case reports of sinonasal ES of the nose or paranasal sinuses have been reported. Furthermore, there has been only 1 case of sinonasal ES arising from the middle turbinate. Recommended management of sinonasal ES stems from the management of its osseous counterpart, ES, but treatment with surgery, radiotherapy, and chemotherapy is varied. Five-year survival rates vary from 21% to 70%, with the lower rates representing patients presenting with metastatic disease.
A 26-year-old man presented with persistent left-sided nasal obstruction. Endoscopy demonstrated a friable mass in the left nasal cavity originating from the middle turbinate with extension into the nasopharynx, confirmed with computed tomography and magnetic resonance imaging. There was no evidence of metastatic disease on positron emission tomography-computed tomography. Histopathologic results were consistent with sinonasal ES. The result of fluorescent in situ hybridization was positive for the EWS gene translocation. A multidisciplinary tumor board evaluated the patient. The patient then underwent neoadjuvant chemotherapy, followed by definitive endoscopic surgical resection and postoperative radiotherapy.
Our literature review found more involvement of the maxillary and ethmoid sinuses compared with the nasal cavity, and that the role of radiation and surgical approach was varied. ES of the sinonasal tract is a rare entity with high mortality, but few standardized treatment protocols exist. Further study and evidence-based treatment protocols are needed. This article outlines the role of relevant imaging, a multidisciplinary team approach, and the optimal timing of surgery, chemotherapy, and radiation.
鼻窦尤因肉瘤(ES)及相关原始神经外胚层肿瘤较为罕见。据我们所知,仅报道过10例鼻腔或鼻窦鼻窦ES病例。此外,仅有1例起源于中鼻甲的鼻窦ES病例。鼻窦ES的推荐治疗方法源自其骨部对应物ES的治疗方法,但手术、放疗和化疗的治疗方式各不相同。五年生存率从21%到70%不等,较低的生存率代表患有转移性疾病的患者。
一名26岁男性因持续性左侧鼻塞就诊。内镜检查显示左侧鼻腔有一个易碎肿物,起源于中鼻甲并延伸至鼻咽部,计算机断层扫描和磁共振成像证实了这一点。正电子发射断层扫描 - 计算机断层扫描未发现转移性疾病的证据。组织病理学结果与鼻窦ES一致。荧光原位杂交结果显示EWS基因易位呈阳性。一个多学科肿瘤委员会对该患者进行了评估。患者随后接受了新辅助化疗,接着进行了确定性内镜手术切除和术后放疗。
我们的文献综述发现,与鼻腔相比,上颌窦和筛窦受累更多,而且放疗和手术方式的作用各不相同。鼻窦ES是一种罕见且死亡率高的疾病,但标准化治疗方案很少。需要进一步研究和基于证据的治疗方案。本文概述了相关影像学检查的作用、多学科团队方法以及手术、化疗和放疗的最佳时机。